Affordable Access

deepdyve-link
Publisher Website

Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis

Authors
  • Gevaert, Philippe
  • VAN BRUAENE, NICHOLAS
  • Cattaert, Tom
  • Van Steen, Kristel
  • Van Zele, Thibaut
  • Acke, Frederic
  • De Ruyck, Natalie
  • Blomme, Katrien
  • Sousa, Anna
  • Marshall, Richard
  • Bachert, Claus
Publication Date
Jan 01, 2011
Identifiers
DOI: 10.1016/j.jaci.2011.07.056
OAI: oai:archive.ugent.be:2034412
Source
Ghent University Institutional Archive
Keywords
Language
English
License
Unknown
External links

Abstract

Background: Approximately 85% of nasal polyps (NPs) in white subjects are characterized by prominent eosinophilia. IL-5 is the key driver of eosinophilic differentiation and survival. Objective: We sought to investigate the therapeutic potential of inhibiting IL-5 with a humanized mAb as treatment for severe nasal polyposis. Methods: Thirty patients with severe nasal polyposis (grade 3 or 4 or recurrent after surgery) refractory to corticosteroid therapy were randomized in a double-blindfashion to receive either 2 single intravenous injections (28 days apart) of 750 mg of mepolizumab (n = 20) or placebo (n = 10). Change from baseline in NP score was assessed monthly until 1 month after the last dose (week 8). Computed tomographic scans were also performed at week 8. Results: Twelve of 20 patients receiving mepolizumab had a significantly improved NP score and computed tomographic scan score compared with 1 of 10 patients receiving placebo at week 8 versus baseline. Conclusion: Mepolizumab achieved a statistically significant reduction in NP size for at least 1 month after dosing in 12 of 20 patients. IL-5 inhibition is a potential novel therapeutic approach in patients with severe eosinophilic nasal polyposis.

Report this publication

Statistics

Seen <100 times